1. Val-HeFT: Valsartan vs placebo in patients with and without renal dysfunction
End point
Valsartan, n (%)
Placebo,
n (%)
Hazard ratio
(95% CI) P*
Death
 0.57
GFR >60
132 (12.8)
141 (13.4)
0.96 ( )
GFR <60
362 (24.5)
341 (23.7)
1.04 ( )
First morbid event
 0.18
117 (11.4)
142 (13.5)
0.83 ( )
249 (16.9)
344 (23.9)
0.68 ( )
First HF hospitalization
GFR > 60
108 (10.5)
133 (12.6)
0.82 ( )
240 (16.3)
330 (22.9)
0.69 ( )
Death or first
morbid event
  0.65
222 (21.6)
250 (23.7)
0.90 ( )
499 (33.8)
549 (38.1)
0.85 ( )
*>60 vs <60
Anand IS. European Society of Cardiology Congress 2005; September 4-7, 2005; Stockholm, Sweden.